Next Article in Journal
Modulation of Distribution and Diffusion through the Lipophilic Membrane with Cyclodextrins Exemplified by a Model Pyridinecarboxamide Derivative
Next Article in Special Issue
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Previous Article in Journal
Development of Thermoresponsive Hydrogels with Mucoadhesion Properties Loaded with Metronidazole Gel-Flakes for Improved Bacterial Vaginosis Treatment
Previous Article in Special Issue
Facile Preparation of Samarium Carbonate-Polymethacrylate Microspheres as a Neutron-Activatable Radioembolic Agent for Hepatic Radioembolization
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 5
10.3390/pharmaceutics15051532
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Tracers for Cardiac Imaging: Targeting the Future of Viable Myocardium

by
Carmela Nappi
1,*,
Mariarosaria Panico
2,
Maria Falzarano
1,
Carlo Vallone
1,
Andrea Ponsiglione
1,
Paolo Cutillo
1,
Emilia Zampella
1,
Mario Petretta
3 and
Alberto Cuocolo
1
1
Department of Advanced Biomedical Sciences, University of Naples Federico II, 80131 Naples, Italy
2
Institute of Biostructure and Bioimaging, National Council of Research, 80131 Naples, Italy
3
IRCCS SYNLAB SDN, Via Gianturco 113, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(5), 1532; https://doi.org/10.3390/pharmaceutics15051532
Submission received: 9 March 2023 / Revised: 2 May 2023 / Accepted: 7 May 2023 / Published: 18 May 2023
(This article belongs to the Special Issue Recent Advances in Radiopharmacy)
Browse Figures
Review Reports Versions Notes

Abstract

:
Ischemic heart disease is the leading cause of mortality worldwide. In this context, myocardial viability is defined as the amount of myocardium that, despite contractile dysfunction, maintains metabolic and electrical function, having the potential for functional enhancement upon revascularization. Recent advances have improved methods to detect myocardial viability. The current paper summarizes the pathophysiological basis of the current methods used to detect myocardial viability in light of the advancements in the development of new radiotracers for cardiac imaging.

1. Introduction

Ischemic heart disease is the leading cause of mortality worldwide and is responsible for 8.9 million global annual deaths [1]. Patients with ischemic cardiomyopathy, i.e., those with coronary artery disease and significant left ventricular (LV) systolic dysfunction, with or without heart failure symptoms, have a poor prognosis [2]. These patients may present a significant amount of dysfunctional—although viable—myocardium, with the potential to recover from akinetic or severely hypokinetic status when perfusion improves [3]. In the early era of coronary artery bypass graft surgery, a large body of literature provided evidence regarding the potential benefits of therapeutic intervention according to the size of viable myocardium demonstrating that patients with dysfunctional viable myocardium have improved survival, unlike those with nonviable myocardium for which there is no significant benefit from coronary artery revascularization compared to medical therapy alone [4,5,6,7]. More recent data from the extended STICH (Surgical Treatment for IsChemic Heart failure) study [8] do not support the idea that a long-term benefit of coronary artery bypass graft in patients with ischemic cardiomyopathy can be associated with a pre-surgical assessment of myocardial viability by imaging tests. Although the presence of viable myocardium was indeed associated with improvement in left ventricular systolic function, irrespective of treatment, such improvement was not significantly linked to long-term survival [8]. As limitations, positron emission tomography (PET) data and late gadolinium enhancement by cardiac magnetic resonance (MR) were not included in the STICH study, and myocardial viability was dichotomized and not considered as a continuum. As regard percutaneous coronary intervention, the REVIVED-BCIS2 (Revascularization for Ischemic Ventricular Dysfunction-British Cardiovascular Intervention Society) trial, differently from STICH extended, showed no added benefit of revascularization over optimal medical therapy in patients with severe ischemic cardiomyopathy [9]. It should be also considered that, besides pump failure, sudden death due to ventricular arrhythmias from the border zone between infarcted and viable myocardium may be relevant in determining the poor prognosis of patients with ischemic cardiomyopathy. In other studies, the presence of extensive viability predicts the response to pharmacological treatment [10] and cardiac resynchronization therapy [11]. Hence, myocardial viability may indicate the possibility of obtaining favorable therapeutic results with a range of interventions, other than coronary artery revascularization. Future research into viability testing should consider their application and results more broadly. In particular, viable myocardium should not be considered as a single entity but as a spectrum, including jeopardized, stunned, early hibernation, and advanced hibernation, the revascularization of which may each yield different pathophysiological benefits (Table 1).
Furthermore, for patients with ischemic cardiomyopathy, the question is not whether they have viable myocardium but how much they have of each type, where it is, whether it is likely to recover and how long this may take. Central to this is the need for multidisciplinary collaboration to integrate, even with the help of machine learning, clinical information with the myocardial and coronary substrate and imaging data. Noninvasive methods for detecting viability, including echocardiography, cardiac MR and perfusion computed tomography (CT), and nuclear medicine techniques such as single-photon emission CT (SPECT) and positron emission tomography (PET) are rapidly evolving [12,13,14,15]. Of note, these methods differ in the pathophysiological principles used for the assessment of myocardial viability, such as preserved membrane and mitochondrial function, presence and degree of contractile reserve, myocardial metabolism, or absence of myocardial scar (Table 2).
Echocardiography is the oldest noninvasive method to study heart and its potential usefulness for assessing viability (mostly by dobutamine stress test) has been demonstrated [16]. Despite the advantages (lower cost, availability and the lack of ionizing radiation or renal toxicity), the procedure carries many limitations such as technical difficulties in acquiring images in patients with poor acoustic windows and low agreement and reliability, especially in case of limited image quality [17]. In addition, myocardial strain analysis has been proposed as a tool to better identify the presence of viable myocardium [18]. Cardiac MR is one of the most accurate techniques in the arsenal. Using contrast-delayed enhancement, it is possible not only to assess the severity and extension of infarcted myocardium but also to investigate myocardial viability [19]. The limited availability of MR technologies and the restricted possibilities to evaluate patients with implantable devices are the principal limitations of this method. Recently, new technological MR-compatible devices (pacemakers and defibrillators) are being increasingly used, but it should be stressed that they may cause significant imaging artifacts [20]. CT scan (by different protocols) shows high accuracy in myocardium trials and infarct detection [21]. An emerging technique, dual-energy CT, seems to be very promising for myocardial studies and it seems to be also useful to investigate myocardial viability for future promising applications [22,23]. Nuclear medicine procedures by PET or SPECT are widely used to assess cardiovascular risk and prognosis and evaluation of therapy in patients with coronary artery disease, and are also useful for assessment of myocardial viability [24]. SPECT imaging by 201Tl and 99mTc-sestamibi has a respectable indication to evaluate myocardial viability [25]. Its use has two important advantages: good availability and few contraindications [26]. PET is useful both for perfusion studies by using 13N-ammonia, 82Rb, or 15O-water and for myocardial viability studies by using radiolabeled 18F-2-deoxy-2-fluoro-D-glucose (FDG) (Figure 1). 18F-FDG PET is the method with the best sensitivity and specificity to investigate myocardial viability and predict functional myocardial recovery after revascularization [27]. Currently, nuclear medicine is on the rise thanks to the development of new radiotracers with great potential to be considered new molecular probes in the near future. The aim of the present review is to summarize the state-of-the-art of available tracers for the evaluation of viable myocardium and to provide an overview of future prospectives.

2. Pathophysiological Bases of Current Tracers

Recurrent episodes of transient post-ischemic dysfunction (myocardial stunning) due to ischemia and reperfusion not so severe or so long as to cause myocellular necrosis as well as a chronically reduced perfusion can initiate a protective state of myocardial down-regulation called “myocardial hibernation”. This is an advanced state of ischemic dysfunction, histologically characterized by myocellular dedifferentiation, change in gene expression, losses of the contractile proteins and alterations of myocardial metabolism, which starts to prefer the use of glucose instead of free fatty acid, with energy production mainly depending on anaerobic glycolysis [13,14]. These changes in potential molecular targets may be used to study different pathophysiological aspects of myocardium injury [15]. Several techniques, all with advantages and limitations, demonstrated the potential usefulness to study myocardial viability, none better than nuclear medicine procedures, including the use of different tracers for PET and SPECT application (Table 3), with the highest sensitivity observed for PET by using dedicated protocols with the administration of 18F-FDG [27].

2.1. PET Tracers

The clinical applicability of 18F-FDG tracer is based on intracellular trapping after phosphorylation because it produces a substrate that is not useful for metabolism but is helpful to detect metabolic cellular changes during ischemia. The imaging evaluation is realized by a semiquantitative method based on comparatively regional uptake of 18F-FDG [27]. To investigate myocardial viability, a combined evaluation of perfusion and metabolism is required [28]. While 18F-FDG tracer can be used to investigate metabolism, perfusion imaging (performed in the rest phase, and the stress phase too but only where necessary) is commonly realized using 13N ammonia or 82Rb tracers. In hypoperfused and dysfunctional myocardium, it is possible to identify cell survival and viability in the presence of 18F-FDG uptake in the same territory (flow-metabolism mismatch) or not viable tissue in case of not-detectable 18F-FDG uptake (flow-metabolism matched defect) [29]. Representative examples of patients with different perfusion-metabolism patterns by combined 82Rb/18F-FDG PET imaging are depicted in Figure 2 and Figure 3.
Of note, a potential further pattern can be observed with reversed perfusion-metabolism mismatch when there is a reduction in 18F-FDG activity in the septum with normal perfusion due to a left bundle branch block [30]. The combined evaluation of metabolism and perfusion is the preferred method to evaluate myocardial viability [31]. However, 18F-FDG administration requires patient preparation (patient fasting for at least 6 h, oral or intravenous glucose load) to stimulate endogenous insulin release and to minimize the variability in substrate setting between patients. After glucose load, insulin can be administered as needed [28]. Many studies have reported the good performance of this method [27,32,33]. A meta-analysis showed a mean sensitivity of 93% and specificity of 58% to predict myocardium recovery and improvement in left ventricular ejection fraction after revascularization [27]. However, it should be considered that the accuracy decreases in diabetic patients, requiring a more complex preparation protocol [34]. Conversely, the evaluation of oxidative metabolism can be used to identify viable myocardium. Considering the possibility to have an early oxidative metabolism after thrombolysis, it has been noted that the left ventricular functional recovery can be related to the improvement in oxidative metabolism, this condition can be investigated by 11C-acetate PET tracer. The reduction in this tracer uptake can be related to a necrotic area in patients with recent myocardial infarction [35]. Free fatty acids are the major energy substrate for healthy cardiac muscle. Thus, palmitate labeled with 11C has been considered a promising candidate to investigate myocardial viability by PET scan. Its uptake and its metabolism can be related to perfusion, oxygenation levels and neurohumoral environment fitting for cardiac metabolism studies. Nevertheless, the difficult washout limited the routine use of this tracer in clinical practice [35]. To investigate simultaneously perfusion and metabolism using one tracer and reducing both radiation exposure and imaging time, the utilization of 15O-water has been also proposed considering the concept that the injured myocardial regions have a reduced capability to provide rapid water exchange. This method, interesting but hardly feasible, is reserved for medical centers equipped with a cyclotron due to the very short 15O radionuclide half-life of 120 s. Regarding this tracer, an excellent study was carried out by Grönman et al. [36]. In a pig model, they demonstrated that the quantification (based on a single-compartment model) of perfusion parameters like myocardial blood flow, perfusion tissue fraction and perfusion tissue index can provide useful data for myocardial viability assessment. However, other studies are elsewhere required.

2.2. SPECT Tracers

201Tl can be used to differentiate between viable and nonviable myocardium [37,38]. This is an analog of potassium, which is present in myocytes and absent in scar tissue; its high first-pass extraction is proportional to coronary blood flow. The initial myocardial activity of 201Tl is driven by the coronary blood flow state at rest whereas the later uptake over the next 4–24 h is determined by the tracer redistribution, depending on cellular membrane integrity. Hibernation may appear as a myocardial perfusion defect on initial imaging due to reduced coronary blood flow at rest but normalizes on the delayed imaging (with or without 201Tl reinjection) from redistribution of the tracer. The sensitivity of viability detection by 201Tl imaging may increase in the late (24 h) reinjection/redistribution protocol compared to the 4 h early redistribution protocol. The radiopharmaceutical activity of 201Tl in rest/redistribution imaging is approximately 3 mCi with a corresponding radiation effective dose of 10–15 mSv. The uptake into the myocyte happens by the Na+/K+-adenosine triphosphate transport system and by facilitative diffusion, too [39]. 201Tl retention requires a whole sarcolemma. The redistribution starts about 15 to 20 min after injection. Watching thallium uptake, retention, and redistribution, using the two main protocols (rest- and stress-redistribution) for myocardial perfusion, sarcolemma membrane function and myocyte metabolic activity to identify myocardial viability can be investigated [40]. For the evaluation of myocardial ischemia, a stress-redistribution protocol is required with 201Tl injected just before peak exercise or at peak pharmacologic vasodilatation. Stress imaging is obtained 15 min after administration. If a fixed perfusion defect is noted, the redistribution images are obtained after 24 h from tracer injection [41]. A meta-analysis reported a mean sensitivity of 87% and a specificity of 54% of 201Tl imaging to predict recovery of left ventricular function after coronary revascularization [42]. 99mTc-labeled tracers (sestamibi and tetrofosmin), are commonly used in the evaluation of ischemia; they can also be used in the same protocols to assess myocardial viability. 99mTc is a lipophilic substrate, it enters in myocytes by passive diffusion. Differently from 201Tl, the redistribution of 99mTc is limited. Uptake and retention of 99mTc require intact mitochondrial and sarcolemma membranes, which reflect myocyte viability. 99mTc sestamibi has been shown to be comparable to 201Tl in its ability to predict regional recovery of function following revascularization [42,43]. However, it should be taken into account that the common 99mTc-labeled tracers cannot be considered ideal tracers given their relatively low first-pass extraction fraction and high liver absorption, although they boast low lung extraction. Conversely, the advent of ultrafast high-sensitivity gamma cameras paved the way to evaluate potential novel probes with high initial absorption of the heart, combined with longer myocardial retention and high heart/background ratios such as 99mTc-Teboroxime [44]. It has been demonstrated that the addition of a short-acting nitrate prior to administration of 99mTc-sestamibi may expand sensitivity [45,46]. The performance of sestamibi SPECT can be considered comparable to that of 201Tl to detect reversible left ventricular dysfunction [47]. Moreover, in patients with myocardial infarction and chronic reduction of left ventricular function, the diagnostic results carried out by the quantitative rest tetrofosmin analysis are similar to results from 201Tl and sestamibi imaging [48]. Knowledge of beta-methyl-iodophenyl-pentadecanoic acid (BMIPP) dates back several decades. In particular, a great effort has been made by Japanese researchers to provide the basis for its possible employment as a novel diagnostic and prognostic probe labeled with 123I to study acute myocardial infarction [49,50,51]. Combined perfusion studies and fatty acid metabolism evaluation by 123I-BMIPP imaging may produce three different situations: defects of both perfusion and fatty acid metabolism imaging, representing scar or nonviable tissue; lower 123I-BMIPP uptake compared to perfusion tracers’ distribution implicating metabolically damaged but viable myocardium; normal uptake of both perfusion and metabolic tracers meaning healthy myocardium. Identification of these perfusion-metabolism correlations helps to detect viable and nonviable myocardium [52]. However, the accuracy of combined SPECT imaging by using 123I-BMIPP and 99mTc-labeled perfusion tracers is lower than the combined imaging by perfusion SPECT and 18F-FDG PET imaging studies. Thus, the latter method is preferred [53].

3. The Way to Future Imaging

The strength of PET as an imaging technique relies on the versatility of positron-emitting radionuclides that can be integrated into important biochemical molecules. Not only can the distribution of these molecules be imaged, but their uptake can be quantified. In this way, it is possible to assess myocardial perfusion, glucose utilization, fatty acid uptake and oxidation, oxygen consumption, contractile function and presynaptic and postsynaptic neuronal activity [54]. Using specific radiotracers, targets of different pathophysiological steps, the state of advancement of ischemic dysfunction may be investigated. This is the aim of the recent advancement in radiotracer development. Novel molecular radioligands have been developed to study specific cellular components of the inflammatory response after myocardial injury [55,56,57,58]. In particular, the remodeling tissue can be investigated using specific tracers as indirect probes of myocardial suffering, identifying different phases of myocardial disease onset, such as the identification of apoptosis, macrophage presence, or fibroblast activation. In this context, a number of novel molecules have been developed and proposed on the research ground. The 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-extracellular loop 1 inverso (DOTA-ECL1i) labeled with 68Ga is a useful peptide for PET scan, with a selectively increased binding in presence of a C-C chemokine receptor type 2 (CCR2) ligand [58,59]. Cells expressing CCR2, like monocyte, T cells, or B cells are present in large numbers in inflammatory states following an acute event such as myocardial infarction. Therefore, 68Ga-DOTA-ECL1i has been recently investigated to track the recruitment, accumulation and resolution of CCR2+ monocytes and macrophages in the injured myocardium in a mouse model, demonstrating its capacity to identify inflammation involving both the infarct and peri-infarct areas [60]. Other studies on its use are required for clinical translation. It also should be taken into account that in response to an injury (ischemic or not), myofibroblasts produce the fibroblast activation protein (FAP) [61]. There are many inputs for fibrosis, such as myocyte death or mechanical stimuli like pressure, volume overload and neurohormonal activation [62]. The persistence of injury supports progressive fibrogenesis over time [63]. Unfortunately, this target stage is the last step of disease. Therefore, new biomarkers of fibroblast activation to investigate the early stages of the pathology are needed, and increasing attention has been focused on 68Ga-FAP inhibitor development [64] because of its capacity to link up with FAP, produced by fibroblast, in an inflammatory status [65]. A high level of FAP in myofibroblasts has been reported in infarcted hearts [66]. Fibroblast activation evaluation and monitoring are possible by 68Ga-FAP inhibitor, and it can be used to investigate myocardial conditions associated with fibroblast activation [66,67]. Recently, mitochondrial membrane integrity has been proposed as a useful candidate to study the condition in myocardial tissue. The opportunity to quantify the membrane potential allows a direct comparison between subjects and it would be particularly relevant to study the state of advancement of ischemic dysfunction [68]. Mitochondria produce most (90%) cellular adenosine triphosphate (ATP) by oxidative phosphorylation [69]. The mitochondrial electron transport chain converts nutrients into energy. Thus, the mitochondrial membrane potential is needed for the conversion of adenosine diphosphate to ATP [70]. A change in the mitochondrial membrane potential produces not only the overproduction of reactive oxygen species but also lower ATP production and an increase in pathological conditions [70]. Alpert, et al. [71] introduced a method to perform in vivo imaging with PET/CT to measure and map the total membrane potential of cells by a cationic lipophilic tracer, the 18F-labeled tetraphenylphosphonium. This method was used for the quantitative mapping of total membrane potential in swine myocardial cells [71]. In a follow-up study, Pelletier-Galarneau et al. [72] confirmed the strength of this methodology and the possibility to apply the technique also in humans demonstrating that in 13 healthy people cellular membrane potential and mitochondrial membrane potential were in excellent agreement with the prior evaluation in vitro [72]. Of note, it has been demonstrated that a strong correlation between changes in the density of adrenergic receptors and viable dysfunctional myocardium exists [73]. Based on this evidence, data studies suggest an interesting application of SPECT 123I-meta-iodo benzyl-guanidine (123I-MIBG) and PET studies by using different innervation tracers such as 18F-Flubrobenguane (FBBG, also known as 18F-LMI-1195), 18F meta-fluorobenzylguanidine (18F-MFBG), or 11C-hydroxyephedrine (11C-HED) [74,75]. An example of a patient with non-viable myocardium and defect of innervation in the same territory is shown in Figure 4. While the use of 23I-MIBG imaging may count on a robust body of literature including large clinical trials, and it boasts widespread availability of the tracer around the world, the lower resolution of gamma cameras as compared with PET scan may represent a limitation. At the same time, 11C-HED PET/CT imaging benefits from the implied advantages of the scan, such as higher temporal and spatial resolution, making possible absolute quantification. However, the short radionuclide half-life requires on-site production of the compound. Yet, the utilization of 18F-labeled sympathetic molecules may overcome this limitation [76]. This may be the dawn of a technique that could be useful to evaluate different patients and their different responses to therapy. Surprising data may also further come from the use of tracers with primary oncological scope to evaluate not only myocardial viability but also cardiac metastatic involvement. In this context, a potential utilization of prostate-specific membrane antigen labeled with 68Ga has been reported [77]. This is consistent with the concept that prostate-specific membrane antigen is upregulated on the endothelial cells of the neovasculature of a variety of other solid tumors [78]. Table 4 provides a list of ongoing clinical trials using cardiovascular imaging tracers and Table 5 illustrates the advantages and limitations of cardiovascular imaging tracers.

4. Conclusions

In the time of personalized medicine, the identification of methods that break down technical and clinical limitations is the new challenge. In the context of research for innovation in cardiovascular imaging, a potential breakthrough could be represented by new tracer development to assess myocardial viable tissue with the ability not only to improve diagnostic performances but also to refine the current knowledge on myocardial viability physiological and pathophysiological patterns.

Author Contributions

Conceptualization, C.N., M.P. (Mario Petretta) and A.C.; methodology, C.N., M.P. (Mariarosaria Panico), M.F.; C.V.; data curation, A.P., P.C.; E.Z. writing—original draft preparation, C.N., M.P. (Mario Petretta) and A.C.; writing—review and editing, C.N., M.P. (Mario Petretta) and A.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ATPadenosine triphosphate
BMIPPbeta-methyl-iodophenyl-pentadecanoic acid
CCRC-C chemokine receptor type
CTcomputed tomography
FAPfibroblast activation protein
FDG2-deoxy-2-fluoro-D-glucose
FBBGflubrobenguane
HEDhydroxyephedrine
MFBGmeta-fluorobenzylguanidine
MIBGmetaiodobenzylguanidine
MRmagnetic resonance
PETpositron emission tomography
SPECTsingle-photon emission computed tomography

References

  1. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 9 December 2022).
  2. Heidenreich, P.A.; Bozkurt, B.; Aguilar, D.; Allen, L.A.; Byun, J.J.; Colvin, M.M.; Deswal, A.; Drazner, M.H.; Dunlay, S.M.; Evers, L.R.; et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022, 145, e895–e1032. [Google Scholar] [CrossRef] [PubMed]
  3. Velazquez, E.J.; Lee, K.L.; Jones, R.H.; Al-Khalidi, H.R.; Hill, J.A.; Panza, J.A.; Michler, R.E.; Bonow, R.O.; Doenst, T.; Petrie, M.C.; et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N. Engl. J. Med. 2016, 374, 1511–1520. [Google Scholar] [CrossRef] [PubMed]
  4. Diamond, G.A.; Forrester, J.S.; deLuz, P.L.; Wyatt, H.L.; Swan, H.J. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am. Heart J. 1978, 95, 204–209. [Google Scholar] [CrossRef] [PubMed]
  5. Braunwald, E.; Rutherford, J.D. Reversible ischemic left ventricular dysfunction: Evidence for the “hibernating myocardium”. J. Am. Coll. Cardiol. 1986, 8, 1467–1470. [Google Scholar] [CrossRef]
  6. Alderman, E.L.; Fisher, L.D.; Litwin, P.; Kaiser, G.C.; Myers, W.O.; Maynard, C.; Levine, F.; Schloss, M. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983, 68, 785–795. [Google Scholar] [CrossRef] [PubMed]
  7. Pegg, T.J.; Selvanayagam, J.B.; Jennifer, J.; Francis, J.M.; Karamitsos, T.D.; Dall’Armellina, E.; Smith, K.L.; Taggart, D.P.; Neubauer, S. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2010, 12, 56. [Google Scholar] [CrossRef] [PubMed]
  8. Panza, J.A.; Ellis, A.M.; Al-Khalidi, H.R.; Holly, T.A.; Berman, D.S.; Oh, J.K.; Pohost, G.M.; Sopko, G.; Chrzanowski, L.; Mark, D.B.; et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N. Engl. J. Med. 2019, 381, 739–748. [Google Scholar] [CrossRef]
  9. Perera, D.; Clayton, T.; O’Kane, P.D.; Greenwood, J.P.; Weerackody, R.; Ryan, M.; Morgan, H.P.; Dodd, M.; Evans, R.; Canter, R.; et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N. Engl. J. Med. 2022, 387, 1351–1360. [Google Scholar] [CrossRef]
  10. Cleland, J.G.; Pennell, D.J.; Ray, S.G.; Coats, A.J.; Macfarlane, P.W.; Murray, G.D.; Mule, J.D.; Vered, Z.; Lahri, A.; Carvedilol hibernating reversible ischaemia trial: Marker of success investigators (2003). Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomised controlled trial. Lancet 2003, 362, 14–21. [Google Scholar] [CrossRef]
  11. Ypenburg, C.; Schalij, M.J.; Bleeker, G.B.; Steendijk, P.; Boersma, E.; Dibbets-Schneider, P.; Stokkel, M.P.; van der Wall, E.E.; Bax, J.J. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur. Heart J. 2007, 28, 33–41. [Google Scholar] [CrossRef]
  12. Garcia, M.J.; Kwong, R.Y.; Scherrer-Crosbie, M.; Taub, C.C.; Blankstein, R.; Lima, J.; Bonow, R.O.; Eshtehardi, P.; Bois, J.P.; American Heart Association Council on Cardiovascular Radiology and Intervention and Council on Clinical Cardiology. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ. Cardiovasc. Imaging 2020, 13, e000053. [Google Scholar] [CrossRef] [PubMed]
  13. Vanoverschelde, J.L.; Wijns, W.; Borgers, M.; Heyndrickx, G.; Depré, C.; Flameng, W.; Melin, J.A. Chronic myocardial hibernation in humans. From bedside to bench. Circulation 1997, 95, 1961–1971. [Google Scholar] [CrossRef] [PubMed]
  14. Wijns, W.; Vatner, S.F.; Camici, P.G. Hibernating myocardium. N. Engl. J. Med. 1998, 339, 173–181. [Google Scholar] [CrossRef] [PubMed]
  15. Gewirtz, H.; Dilsizian, V. Myocardial viability: Survival mechanisms and molecular imaging targets in acute and chronic ischemia. Circ. Res. 2017, 120, 1197–1212. [Google Scholar] [CrossRef]
  16. Cheirif, J.; Murgo, J.P. Assessment of myocardial viability by dobutamine echocardiography. Coron. Artery Dis. 1995, 6, 600–605. [Google Scholar] [CrossRef]
  17. Hoffmann, R.; Lethen, H.; Marwick, T.; Arnese, M.; Fioretti, P.; Pingitore, A.; Picano, E.; Buck, T.; Erbel, R.; Flachskampf, F.A.; et al. Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. J. Am. Coll. Cardiol. 1996, 27, 330–336. [Google Scholar] [CrossRef]
  18. Amzulescu, M.S.; De Craene, M.; Langet, H.; Pasquet, A.; Vancraeynest, D.; Pouleur, A.C.; Vanoverschelde, J.L.; Gerber, B.L. Myocardial strain imaging: Review of general principles, validation, and sources of discrepancies. Eur. Heart J. Cardiovasc. Imaging 2019, 20, 605–619. [Google Scholar] [CrossRef]
  19. Shah, D.V.; Kalekar, D.T.; Gupta, D.A.; Lamghare, D.P. Role of late gadolinium enhancement in the assessment of myocardial viability. Cureus 2022, 14, e22844. [Google Scholar] [CrossRef]
  20. Parikh, K.; Choy-Shan, A.; Ghesani, M.; Donnino, R. Multimodality imaging of myocardial viability. Curr. Cardiol. Rep. 2021, 23, 5. [Google Scholar] [CrossRef]
  21. Minamimoto, R.; Nakajima, K.; Okazaki, O. Proliferation PET tracer 11C-4DST PET/CT depicts hibernating myocardium. J. Nucl. Cardiol. 2021, 28, 2379–2383. [Google Scholar] [CrossRef]
  22. Dell’Aversana, S.; Ascione, R.; De Giorgi, M.; De Lucia, D.R.; Cuocolo, R.; Boccalatte, M.; Sibilio, G.; Napolitano, G.; Muscogiuri, G.; Sironi, S.; et al. Dual-energy CT of the heart: A review. J. Imaging 2022, 8, 236. [Google Scholar] [CrossRef] [PubMed]
  23. Ji, Q.; Wang, Y.; Zhao, Y.; Chen, Q.; Gao, Y.; Zhou, M.; Liu, B.; Han, R.; Sun, K. Evaluation of myocardial viability in patients with myocardial ischemia reperfusion injury using the dual-energy CT myocardial blood pool imaging. Eur. Radiol. 2022. [Google Scholar] [CrossRef] [PubMed]
  24. Acampa, W.; Petretta, M.; Cuocolo, A. Nuclear medicine procedures in cardiovascular diseases: An evidence-based approach. Q. J. Nucl. Med. 2002, 46, 323–330. [Google Scholar] [PubMed]
  25. Klocke, F.J.; Baird, M.G.; Lorell, B.H.; Bateman, T.M.; Messer, J.V.; Berman, D.S.; O’Gara, P.T.; Carabello, B.A.; Russell, R.O.; Cerqueira, M.D., Jr.; et al. American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J. Am. Coll. Cardiol. 2003, 42, 1318–1333. [Google Scholar]
  26. Bax, J.J.; Poldermans, D.; Elhendy, A.; Boersma, E.; Rahimtoola, S.H. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr. Probl. Cardiol. 2001, 26, 147–186. [Google Scholar] [CrossRef]
  27. Dilsizian, V.; Bacharach, S.L.; Beanlands, R.S.; Bergmann, S.R.; Delbeke, D.; Dorbala, S.; Gropler, R.J.; Knuuti, J.; Schelbert, H.R.; Travin, M.I. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J. Nucl. Cardiol. 2016, 23, 1187–1226. [Google Scholar] [CrossRef]
  28. Slart, R.H.; Bax, J.J.; van der Wall, E.E.; van Veldhuisen, D.J.; Jager, P.L.; Dierckx, R.A. Nuclear cardiac imaging for the assessment of myocardial viability. Neth. Heart J. 2005, 13, 408–415. [Google Scholar]
  29. Thompson, K.; Saab, G.; Birnie, D.; Chow, B.J.; Ukkonen, H.; Ananthasubramaniam, K.; Dekemp, R.A.; Garrard, L.; Ruddy, T.D.; Dasilva, J.N.; et al. Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardiomyopathy? J. Nucl. Med. 2006, 47, 1763–1768. [Google Scholar]
  30. Kobylecka, M.; Mączewska, J.; Fronczewska-Wieniawska, K.; Mazurek, T.; Płazińska, M.T.; Królicki, L. Myocardial viability assessment in 18FDG PET/CT study (18FDG PET myocardial viability assessment). Nucl. Med. Rev. Cent. East. Eur. 2012, 15, 52–60. [Google Scholar] [CrossRef]
  31. Di Carli, M.F.; Asgarzadie, F.; Schelbert, H.R.; Brunken, R.C.; Laks, H.; Phelps, M.E.; Maddahi, J. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995, 92, 3436–3444. [Google Scholar] [CrossRef]
  32. Beanlands, R.S.; Ruddy, T.D.; deKemp, R.A.; Iwanochko, R.M.; Coates, G.; Freeman, M.; Nahmias, C.; Hendry, P.; Burns, R.J.; Lamy, A.; et al. Positron emission tomography and recovery following revascularization (PARR-1): The importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J. Am. Coll. Cardiol. 2002, 40, 1735–1743. [Google Scholar] [CrossRef] [PubMed]
  33. Medical Advisory Secretariat. Positron emission tomography for the assessment of myocardial viability: An evidence-based analysis. Ont. Health Technol. Assess. Ser. 2005, 5, 1–167. [Google Scholar]
  34. Saha, G.B.; MacIntyre, W.J.; Brunken, R.C.; Go, R.T.; Raja, S.; Wong, C.O.; Chen, E.Q. Present assessment of myocardial viability by nuclear imaging. Semin. Nucl. Med. 1996, 26, 315–335. [Google Scholar] [CrossRef] [PubMed]
  35. Henes, C.G.; Bergmann, S.R.; Walsh, M.N.; Sobel, B.E.; Geltman, E.M. Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. J. Nucl. Med. 1989, 30, 1489–1499. [Google Scholar]
  36. Grönman, M.; Tarkia, M.; Stark, C.; Vähäsilta, T.; Kiviniemi, T.; Lubberink, M.; Halonen, P.; Kuivanen, A.; Saunavaara, V.; Tolvanen, T.; et al. Assessment of myocardial viability with [15O]water PET: A validation study in experimental myocardial infarction. J. Nucl. Cardiol. 2021, 28, 1271–1280. [Google Scholar] [CrossRef]
  37. Cuocolo, A.; Nicolai, E.; Petretta, M.; Morisco, C.; De Luca, N.; Salvatore, M.; Trimarco, B. One-year effect of myocardial revascularization on resting left ventricular function and regional thallium uptake in chronic CAD. J. Nucl. Med. 1997, 38, 1684–1692. [Google Scholar]
  38. Cuocolo, A.; Petretta, M.; Nicolai, E.; Pace, L.; Bonaduce, D.; Salvatore, M.; Trimarco, B. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging. Eur. J. Nucl. Med. 1998, 25, 60–68. [Google Scholar] [CrossRef]
  39. Berger, B.C.; Petretta, M.; Cuocolo, A.; Bonaduce, D.; Nicolai, E.; Cardei, S.; Berardino, S.; Ianniciello, A.; Apicella, C.; Bianchi, V.; et al. Incremental prognostic value of thallium reinjection after stress-redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction. J. Nucl. Med. 1997, 38, 195–200. [Google Scholar]
  40. Dilsizian, V.; Rocco, T.P.; Freedman, N.M.; Leon, M.B.; Bonow, R.O. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N. Engl. J. Med. 1990, 323, 141–146. [Google Scholar] [CrossRef]
  41. Schinkel, A.F.; Bax, J.J.; Poldermans, D.; Elhendy, A.; Ferrari, R.; Rahimtoola, S.H. Hibernating myocardium: Diagnosis and patient outcomes. Curr. Probl. Cardiol. 2007, 32, 375–410. [Google Scholar] [CrossRef]
  42. Udelson, J.E.; Coleman, P.S.; Metherall, J.; Pandian, N.G.; Gomez, A.R.; Griffith, J.L.; Shea, N.L.; Oates, E.; Konstam, M.A. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994, 89, 2552–2561. [Google Scholar] [CrossRef] [PubMed]
  43. Bisi, G.; Sciagrà, R.; Santoro, G.M.; Fazzini, P.F. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J. Am. Coll. Cardiol. 1994, 24, 1282–1289. [Google Scholar] [CrossRef] [PubMed]
  44. Boschi, A.; Uccelli, L.; Marvelli, L.; Cittanti, C.; Giganti, M.; Martini, P. Technetium-99m Radiopharmaceuticals for Ideal Myocardial Perfusion Imaging: Lost and Found Opportunities. Molecules 2022, 10, 1188. [Google Scholar] [CrossRef] [PubMed]
  45. Sciagrà, R.; Bisi, G.; Santoro, G.M.; Zerauschek, F.; Sestini, S.; Pedenovi, P.; Pappagallo, R.; Fazzini, P.F. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery. J. Am. Coll. Cardiol. 1997, 30, 384–391. [Google Scholar] [CrossRef]
  46. Cuocolo, A.; Acampa, W.; Nicolai, E.; Pace, L.; Petretta, M.; Salvatore, M. Quantitative thallium-201 and technetium 99m sestamibi tomography at rest in detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction. J. Nucl. Cardiol. 2000, 7, 8–15. [Google Scholar] [CrossRef]
  47. Acampa, W.; Cuocolo, A.; Petretta, M.; Bruno, A.; Castellani, M.; Finzi, A.; Gerundini, P. Tetrofosmin imaging in the detection of myocardial viability in patients with previous myocardial infarction: Comparison with sestamibi and Tl-201 scintigraphy. J. Nucl. Cardiol. 2002, 9, 33–40. [Google Scholar] [CrossRef]
  48. Nishimura, T.; Uehara, T.; Shimonagata, T.; Nagata, S.; Haze, K. Clinical experience of 1231-BMIPP myocardial imaging for myocardial infarction and hypertrophic cardiomyopathy. Ann. Nucl. Med. 1993, 7, 35–40. [Google Scholar]
  49. Kurata, C.; Tawahara, K.; Okayama, K.; Kenichi, W.; Yasushi, K.; Akira, Y.; Noboru, K.M. Myocardial imaging with radioiodinated beta-methyl-branched fatty acid in cardiomyopathy. Ann. Nucl. Med. 1993, 7 (Suppl. 2), 27–33. [Google Scholar]
  50. Biswas, S.K.; Sarai, M.; Hishida, H.; Ozaki, Y. 123I-BMIPP fatty acid analogue imaging is a novel diagnostic and prognostic approach following acute myocardial infarction. Singap. Med. J. 2009, 50, 943–948. [Google Scholar]
  51. Nakata, T.; Hashimoto, A.; Eguchi, M. Cardiac BMIPP imaging in acute myocardial infarction. Int. J. Card. Imaging 1999, 15, 21–26. [Google Scholar] [CrossRef]
  52. Seki, H.; Toyama, T.; Higuchi, K.; Kasama, S.; Ueda, T.; Seki, R.; Hatori, T.; Endo, K.; Kurabayashi, M. Prediction of functional improvement of ischemic myocardium with (123I-BMIPP SPECT and 99mTc-tetrofosmin SPECT imaging: A study of patients with large acute myocardial infarction and receiving revascularization therapy. Circ. J. 2005, 69, 311–319. [Google Scholar] [CrossRef] [PubMed]
  53. Underwood, S.R.; Bax, J.J.; vom Dahl, J.; Henein, M.Y.; Knuuti, J.; van Rossum, A.C.; Schwarz, E.R.; Vanoverschelde, J.L.; van der Wall, E.E.; Wijns, W.; et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group. of the European Society of Cardiology. Eur. Heart J. 2004, 25, 815–836. [Google Scholar] [CrossRef] [PubMed]
  54. Glasenapp, A.; Hess, A.; Thackeray, J.T. Molecular imaging in nuclear cardiology: Pathways to individual precision medicine. J. Nucl. Cardiol. 2020, 27, 2195–2201. [Google Scholar] [CrossRef]
  55. Borchert, T.; Beitar, L.; Langer, L.B.N.; Polyak, A.; Wester, H.J.; Ross, T.L.; Hilfiker-Kleiner, D.; Bengel, F.M.; Thackeray, J.T. Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. J. Nucl. Cardiol. 2021, 28, 1636–1645. [Google Scholar] [CrossRef] [PubMed]
  56. Wargocka-Matuszewska, W.; Uhrynowski, W.; Rozwadowska, N.; Rogulski, Z. Recent advances in cardiovascular diseases research using animal models and PET radioisotope tracers. Int. J. Mol. Sci. 2022, 24, 353. [Google Scholar] [CrossRef] [PubMed]
  57. Thackeray, J.T.; Bengel, F.M. Molecular imaging of myocardial inflammation with positron emission tomography post-ischemia: A determinant of subsequent remodeling or recovery. JACC Cardiovasc. Imaging 2018, 11, 1340–1355. [Google Scholar] [CrossRef]
  58. Heo, G.S.; Kopecky, B.; Sultan, D.; Ou, M.; Feng, G.; Bajpai, G.; Zhang, X.; Luehmann, H.; Detering, L.; Su, Y.; et al. Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart. Circ. Res. 2019, 124, 881–890. [Google Scholar] [CrossRef]
  59. Liu, Y.; Li, W.; Luehmann, H.P.; Zhao, Y.; Detering, L.; Sultan, D.H.; Hsiao, H.M.; Krupnick, A.S.; Gelman, A.E.; Combadiere, C.; et al. Noninvasive imaging of CCR2+ cells in ischemia-reperfusion injury after lung transplantation. Am. J. Transplant. 2016, 16, 3016–3023. [Google Scholar] [CrossRef]
  60. Hess, A.; Thackeray, J.T.; Wollert, K.C.; Bengel, F.M. Radionuclide image-guided repair of the heart. JACC Cardiovasc. Imaging 2020, 13, 2415–2429. [Google Scholar] [CrossRef]
  61. Wynn, T.A.; Ramalingam, T.R. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat. Med. 2012, 18, 1028–1040. [Google Scholar] [CrossRef]
  62. Segura, A.M.; Frazier, O.H.; Buja, L.M. Fibrosis and heart failure. Heart Fail. Rev. 2014, 19, 173–185. [Google Scholar] [CrossRef] [PubMed]
  63. Ponsiglione, A.; Ascione, R.; Nappi, C.; Imbriaco, M.; Klain, M.; Cuocolo, R.; Cuocolo, A.; Petretta, M. Cardiac hybrid imaging: Novel tracers for novel targets. J. Geriatr. Cardiol. 2021, 18, 748–758. [Google Scholar] [PubMed]
  64. Garin-Chesa, P.; Old, L.J.; Rettig, W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 1990, 87, 7235–7239. [Google Scholar] [CrossRef] [PubMed]
  65. Rettig, W.J.; Garin-Chesa, P.; Healey, J.H.; Su, S.L.; Jaffe, E.A.; Old, L.J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA 1992, 89, 10832–10836. [Google Scholar] [CrossRef]
  66. Varasteh, Z.; Mohanta, S.; Robu, S.; Braeuer, M.; Li, Y.; Omidvari, N.; Topping, G.; Sun, T.; Nekolla, S.G.; Richter, A.; et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J. Nucl. Med. 2019, 60, 1743–1749. [Google Scholar] [CrossRef]
  67. Creemers, E.E.; Pinto, Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 2011, 89, 265–272. [Google Scholar] [CrossRef]
  68. Rich, P. Chemiosmotic coupling: The cost of living. Nature 2003, 421, 583. [Google Scholar] [CrossRef]
  69. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. and Walter, P. Molecular biology of the cell. 4th edn. Ann. Bot. 2003, 91, 401. [CrossRef]
  70. Hüttemann, M.; Lee, I.; Pecinova, A.; Pecina, P.; Przyklenk, K.; Doan, J.W. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J. Bioenerg. Biomembr. 2008, 40, 445–456. [Google Scholar] [CrossRef]
  71. Alpert, N.M.; Guehl, N.; Ptaszek, L.; Pelletier-Galarneau, M.; Ruskin, J.; Mansour, M.C.; Wooten, D.; Ma, C.; Takahashi, K.; Zhou, Y.; et al. Quantitative in vivo mapping of myocardial mitochondrial membrane potential. PLoS ONE 2018, 13, e0190968. [Google Scholar] [CrossRef]
  72. Pelletier-Galarneau, M.; Petibon, Y.; Ma, C.; Han, P.; Kim, S.J.W.; Detmer, F.J.; Yokell, D.; Guehl, N.; Normandin, M.; El Fakhri, G.; et al. In vivo quantitative mapping of human mitochondrial cardiac membrane potential: A feasibility study. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 414–420. [Google Scholar] [CrossRef] [PubMed]
  73. Shan, K.; Bick, R.J.; Poindexter, B.J.; Nagueh, S.F.; Shimoni, S.; Verani, M.S.; Keng, F.; Reardon, M.J.; Letsou, G.V.; Howell, J.F.; et al. Altered adrenergic receptor density in myocardial hibernation in humans: A possible mechanism of depressed myocardial function. Circulation 2000, 102, 2599–2606. [Google Scholar] [CrossRef] [PubMed]
  74. Travin, M.I.; Henzlova, M.J.; van Eck-Smit, B.L.F.; Jain, D.; Carrió, I.; Folks, R.D.; Garcia, E.V.; Jacobson, A.F.; Verberne, H.J. Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk. J. Nucl. Cardiol. 2017, 24, 377–391. [Google Scholar] [PubMed]
  75. Travin, M.I. Can the promise of radionuclide cardiac innervation imaging be fulfilled? J. Nucl. Cardiol. 2022, 29, 3189–3193. [Google Scholar] [CrossRef]
  76. Kobayashi, R.; Chen, X.; Werner, R.A.; Lapa, C.; Javadi, M.S.; Higuchi, T. New horizons in cardiac innervation imaging: Introduction of novel 18F-labeled PET tracers. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 2302–2309. [Google Scholar] [CrossRef] [PubMed]
  77. Das, J.P.; Yeh, R. Prostate cancer cardiac metastasis detected on serial imaging with [68Ga] PSMA-11 PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 3952–3953. [Google Scholar] [CrossRef]
  78. Van de Wiele, C.; Sathekge, M.; de Spiegeleer, B.; De Jonghe, P.J.; Debruyne, P.R.; Borms, M.; Beels, L.; Maes, A. PSMA expression on neovasculature of solid tumors. Histol. Histopathol. 2020, 35, 919–927. [Google Scholar]
Pharmaceutics 15 01532 g001 550
Figure 1. Patient with a large area (yellow arrows) of hypoperfused (82Rb PET/MR) and nonviable (18F-FDG PET/CT) myocardium in the inferolateral wall of the left ventricle corresponding to an MR pattern of late gadolinium enhancement (LGE) in the same region.
Figure 1. Patient with a large area (yellow arrows) of hypoperfused (82Rb PET/MR) and nonviable (18F-FDG PET/CT) myocardium in the inferolateral wall of the left ventricle corresponding to an MR pattern of late gadolinium enhancement (LGE) in the same region.
Pharmaceutics 15 01532 g001
Pharmaceutics 15 01532 g002 550
Figure 2. Patient with severe hypoperfusion and preserved metabolic activity in the apex and the apical segment of the anteroseptal region of the left ventricle by combined 82Rb/18F-FDG PET/CT cardiac imaging. Slice review (A) and polar maps (B) indicate a mismatch pattern that suggests the presence of hypoperfused but viable myocardium.
Figure 2. Patient with severe hypoperfusion and preserved metabolic activity in the apex and the apical segment of the anteroseptal region of the left ventricle by combined 82Rb/18F-FDG PET/CT cardiac imaging. Slice review (A) and polar maps (B) indicate a mismatch pattern that suggests the presence of hypoperfused but viable myocardium.
Pharmaceutics 15 01532 g002
Pharmaceutics 15 01532 g003 550
Figure 3. Patient with absent perfusion and no evidence of metabolic activity in the apex and the apical segment of the anteroseptal region of the left ventricle by combined 82Rb/18F-FDG PET/CT cardiac imaging. Slice review (A) and polar maps (B) indicate a match pattern that suggests the presence of necrotic myocardium. Analysis of tracer uptake is performed in 17 myocardial segments by use of a 5-point scoring system (from 0, normal uptake to 4, absence of detectable tracer uptake).
Figure 3. Patient with absent perfusion and no evidence of metabolic activity in the apex and the apical segment of the anteroseptal region of the left ventricle by combined 82Rb/18F-FDG PET/CT cardiac imaging. Slice review (A) and polar maps (B) indicate a match pattern that suggests the presence of necrotic myocardium. Analysis of tracer uptake is performed in 17 myocardial segments by use of a 5-point scoring system (from 0, normal uptake to 4, absence of detectable tracer uptake).
Pharmaceutics 15 01532 g003
Pharmaceutics 15 01532 g004 550
Figure 4. Example of dual isotope 123I-MIBG/99mTc-sestamibi imaging obtained with CZT camera in a patient with hypertension and dyslipidemia and heart failure. Tomographic images (first row 123I-MIBG, second row 99mTc-sestamibi) demonstrating innervation and perfusion defect on the inferior wall of the left ventricle with a total defect score (TDS) of 35.
Figure 4. Example of dual isotope 123I-MIBG/99mTc-sestamibi imaging obtained with CZT camera in a patient with hypertension and dyslipidemia and heart failure. Tomographic images (first row 123I-MIBG, second row 99mTc-sestamibi) demonstrating innervation and perfusion defect on the inferior wall of the left ventricle with a total defect score (TDS) of 35.
Pharmaceutics 15 01532 g004
Table
Table 1. Different myocardial states.
Table 1. Different myocardial states.
FunctionPerfusionMetabolismInotropic ResponseFunctional Recovery
Stunned
(viable)		ReducedNormalYesYesYes
Hibernating
(viable)		ReducedReducedYesYesYes
Necrotic
(non-viable)		ReducedReducedNoNoNo
Table
Table 2. Noninvasive imaging methods to assess myocardial viability.
Table 2. Noninvasive imaging methods to assess myocardial viability.
MeasureViability Marker
SPECT201Tl or 99mTc uptakeMyocyte membrane integrity
PET18F-FDG uptakeGlucose metabolism
Stress echocardiographyInotropic stimulationContractile reserve
Cardiac MRLate gadolinium enhancementExtracellular volume
SPECT: single-photon emission computed tomography, PET: positron emission tomography, FDG: 2-deoxy-2-fluoro-D-glucose, MR: magnetic resonance.
Table
Table 3. Characteristics of radiotracers for imaging myocardial viability.
Table 3. Characteristics of radiotracers for imaging myocardial viability.
TracerHalf-LifePathwayEmissionEnergy (MeV)
18F-FDG110 minHexokinase/glucose metabolismβ+0.633
11C-acetate20 minKrebs cycle/free fatty acid metabolismβ+,0.961
15O-water2 minPassive diffusion/blood flowβ+0.019
68Ga-DOTA-ECL1i68 minCCR type 2/inflammatory response to injuryβ+1.899
68Ga-FAPI68 minFAP/inflammatory response to injuryβ+1.899
18F-tetraphenylphosphonium110 minMitochondria/mitochondrial membrane integrityβ+0.633
123I-MIBG13.2 hDistribution and integrity of adrenergic nerve endingsγ0.159
18F-FBBG (or 18F-LMI-1195)110 minDistribution and integrity of adrenergic nerve endingsβ+0.633
18F-MFBG110 minDistribution and integrity of adrenergic nerve endingsβ+0.633
11C-HED20 minDistribution and integrity of adrenergic nerve endingsβ+0.961
201Tl72.9 hNa+/K+ pump/blood flowγ0.135, 0.167
123I-BMIPP13.2 hKrebs cycle/free fatty acid metabolismγ0.159
99mTc-Sestamibi6 hMitochondria and cytosol proteins in myocytesγ0.140
99mTc-Tetrofosmin6 hMitochondria and cytosol proteins in myocytesγ0.140
FDG: 2-deoxy-2-fluoro-D-glucose, DOTA-ECL1i: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-extracellular loop 1 inverso, CCR: C-C chemokine receptor, FAPI: fibroblast activation protein inhibitor, MIBG: metaiodobenzylguanidine, FBBG: flubrobenguane, MFBG: meta-fluorobenzylguanidine, HED: hydroxyephedrine, BMIPP, beta-methyl-iodophenyl-pentadecanoic acid.
Table
Table 4. Current ongoing clinical trials using cardiovascular imaging perfusion and viability tracers.
Table 4. Current ongoing clinical trials using cardiovascular imaging perfusion and viability tracers.
Project TitleSponsorsStudy TypeAimStatus
Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group (GALMYDAR)Washington University School of Medicine, USAInterventionalTo evaluate dosimetry, biodistribution, safety and imaging characteristics following a single 68Ga-Galmydar injection in normal healthy volunteersRecruiting completed
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial AngiogenesisRigshospitalet, DenmarkInterventionalTo examine the expression of αvβ3 integrin using a novel radiotracer in patients with myocardial infarction and investigate if it is a suitable tool for predicting myocardial recovery and prognosisRecruiting completed
Cardiac FDG PET Viability Registry (CADRE)Ottawa Heart Institute Research Corporation, CanadaObservationalTo evaluate the utility of FDG PET imaging in the decision-making process for patients with poor left ventricular function who may be candidates for revascularization and to study the downstream effect of the clinical management decisionsRecruiting
Open-Label, Exploratory, Phase 1/2 Scintigraphy Study Evaluating 18F-mFBG for Imaging Myocardial Sympathetic Innervation in Subjects Without and With Heart DiseaseInnervate Radiopharmaceuticals LLC, USAInterventionalTo observe the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervationRecruiting
Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O-H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Conditions Using PET Imaging (RAPID-WATER-FLOW)MedTrace Pharma A/S, DenmarkInterventionalTo evaluate the sensitivity and specificity of the 15O-H2O PET study using the truth-standard of ICA with FFR or CCTARecruiting
Table
Table 5. Advantages and limitations of cardiovascular imaging tracers.
Table 5. Advantages and limitations of cardiovascular imaging tracers.
TracerAdvantagesLimitations
18F-FDGLong radionuclide half-life allowing delivery; high temporal and spatial resolution of equipment; robust evidenceMetabolic compensation needed; perfusion study required for a combined evaluation
11C-acetateSingle-tracer technique; minimal metabolic dependenceOn-site cyclotron required
15O-waterHigh and linear tracer; uptake rate into myocardium; high temporal and spatial resolution of equipmentOn-site cyclotron required; technical demanding protocols
68Ga-DOTA-ECL1iCommercially available 68Ge/68Ga generator for multiple daily studies; rapid clearance; low liver retentionVery limited data available; low specificity
68Ga-FAPICommercially available 68Ge/68Ga generator for multiple daily studies; high abnormal/normal uptake ratioLimited data available; low specificity
18F-tetraphenylphosphoniumLong radionuclide half-life allowing delivery; High temporal and spatial resolution of equipment; first voltage non-invasive probeLimited data available; no gold standard method as reference; high distribution heterogeneity
123I-MIBGRobust evidence; optimal storage in neuronal vesicles; highly specific tracer; high heart-to-background ratios with clear cardiac imagesLow resolution of equipment; standardization protocols still required
18F-FBBG (or 18F-LMI-1195)Simple radiolabeling; procedure for commercial use; high heart-to-background ratios with clear cardiac images; high temporal and spatial resolution of equipmentLimited data available
18F-MFBGOptimal storage in neuronal vesicles; highly specific tracer; high heart-to-background ratios with clear cardiac images; high temporal and spatial resolution of equipmentLimited data available
11C-HEDRobust evidence; highly specific tracer; high heart-to-background ratios with clear cardiac images high temporal and spatial resolution of equipmentOn-site cyclotron required; delayed scans for turnover assessment not feasible due to low radionuclide half-life; high lipophilicity with potential tracer loss across lipid membranes
201TlTissue concentration proportional to flow; potential evaluation of perfusion and viabilityLow resolution of equipment; dosimetric issues
123I-BMIPPPrimary energy cardiac source tracer; high specificityLow resolution of equipment; low sensitivity
99mTc-Sestamibi and 99mTc-TetrofosminShort radionuclide half-life with a feasible dosimetric profile; myocardial uptake proportional to the integrity of membrane with high accuracyLow resolution of equipment; low first-pass extraction fraction and high liver absorption
FDG: 2-deoxy-2-fluoro-D-glucose, DOTA-ECL1i: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-extracellular loop 1 inverso, CCR: C-C chemokine receptor, FAPI: fibroblast activation protein inhibitor, MIBG: metaiodobenzylguanidine, FBBG: flubrobenguane, MFBG: meta-fluorobenzylguanidine, HED: hydroxyephedrine, BMIPP, beta-methyl-iodophenyl-pentadecanoic acid.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nappi, C.; Panico, M.; Falzarano, M.; Vallone, C.; Ponsiglione, A.; Cutillo, P.; Zampella, E.; Petretta, M.; Cuocolo, A. Tracers for Cardiac Imaging: Targeting the Future of Viable Myocardium. Pharmaceutics 2023, 15, 1532. https://doi.org/10.3390/pharmaceutics15051532

AMA Style

Nappi C, Panico M, Falzarano M, Vallone C, Ponsiglione A, Cutillo P, Zampella E, Petretta M, Cuocolo A. Tracers for Cardiac Imaging: Targeting the Future of Viable Myocardium. Pharmaceutics. 2023; 15(5):1532. https://doi.org/10.3390/pharmaceutics15051532

Chicago/Turabian Style

Nappi, Carmela, Mariarosaria Panico, Maria Falzarano, Carlo Vallone, Andrea Ponsiglione, Paolo Cutillo, Emilia Zampella, Mario Petretta, and Alberto Cuocolo. 2023. "Tracers for Cardiac Imaging: Targeting the Future of Viable Myocardium" Pharmaceutics 15, no. 5: 1532. https://doi.org/10.3390/pharmaceutics15051532

APA Style

Nappi, C., Panico, M., Falzarano, M., Vallone, C., Ponsiglione, A., Cutillo, P., Zampella, E., Petretta, M., & Cuocolo, A. (2023). Tracers for Cardiac Imaging: Targeting the Future of Viable Myocardium. Pharmaceutics, 15(5), 1532. https://doi.org/10.3390/pharmaceutics15051532

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop